PB0082 - Biomarkers in COVID-19: Association with disease severity and outcomes

Sunday, July 10, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

Maria Rita Peralta, BACHELOR

Haematology Consultant
Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust. London, United Kingdom
LONDON, England, United Kingdom

Co-Author(s)

VM

Vincent Muczynski

Research Fellow
University College London (UCL)
London, England, United Kingdom
PL

Philip Lane

Biomedical scientist
Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust. London, United Kingdom
London, England, United Kingdom
LP

Liezelle Pagala

Biomedical scientist
Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust. London, United Kingdom
London, England, United Kingdom
AR

Anne Riddell

Laboratory Head of Department (Special Coagulation, Haemophilia) and HSL Scientific Lead Coagulation
Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK
London, England, United Kingdom
Sb

Sanjay bhagani

Consultant Physician/Hon.Associate Professor Department of Infectious Disease/HIV Medicine
Department of Infectious Diseases, Royal Free London NHS Foundation Trust, London, UK
London, England, United Kingdom
BA

Banwari Agarwal

Consultant at the Department of Critical Care, Royal Free Hospital,London
Department of Intensive care and Anaesthesia, Royal Free London NHS Foundation Trust, London, UK
London, England, United Kingdom
KG

Keith Gomez

Consultant Haematologist
Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK
London, England, United Kingdom
AD

Anja Drebes

Consultant Haematologist
Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK
London, England, United Kingdom
John H. McVey, PhD

Professor of Cardiovascular Biology, University of Surrey
Department of Biomedical Sciences, University of Surrey, Guilford, UK
Guilford, England, United Kingdom
TK

Tushar Kotecha

Consultant Cardiologist
Royal Free London NHS Foundation Trust, London, UK
London, England, United Kingdom
DM

Daniel Martin

Professor of Perioperative and Intensive Care Medicine
Department of Intensive care and Anaesthesia, Royal Free London NHS Foundation Trust, London, UK
London, England, United Kingdom
AD

Andrew Davenport

Professor of Dialysis&ICU Nephrology UCL Department of Nephrology
Royal Free London NHS Foundation Trust, London, UK
London, England, United Kingdom
AL

Arian Laurence

Consultant
University College of London, London, UK
London, England, United Kingdom
AB

Arndt Brachat

Statistician
Biozentrum, University of Basel
Basel, Basel-Landschaft, Switzerland
TS

Tara Sood

Consultant in Emergency Medicine
Royal Free London NHS Foundation Trust, London, UK
London, England, United Kingdom
LL

Lesley Lanning

Senior Biomedical Scientist
Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust. London, United Kingdom
London, England, United Kingdom
TG

Tejas Gandhi

Senior Biomedical Scientist
Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London, UK
London, England, United Kingdom
Pratima Chowdary, MD

Consultant Haematologist
Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London, United Kingdom
London, England, United Kingdom

Background: In coronavirus disease 2019 (COVID-19) the need for intervention increases with disease severity and a risk prediction model that incorporates biomarkers would be beneficial for identifying patients for treatment escalation.

Aims: To investigate biomarkers changes associated with disease severity and outcomes (mortality, thrombosis).

Methods: COVID-19 patients were sampled between April 15 and May 31 2020. Disease severity was assessed by World Health Organization (WHO) ordinal scale. 132 systemic biomarkers were investigated by routine and multiplex assays and statistical analysis performed to characterise the biomarker profile of COVID-19 patients associated with disease severity, duration, survival and thrombosis.

Results: The study enrolled 150 COVID-19 positive adults and 16 healthy volunteers. The average age was 64 years, 59% were male, 85% had co-morbidities, 33% had a thrombotic event, and 13% died. A cross comparative analysis of biomarkers identified 13 biomarkers common to severity, mortality and thrombosis with significant correlation; including endothelial dysfunction (VWF, tPA, TFPI), hypercatabolism (low albumin, Hb, FXIII) and inflammatory response (IL-8, Osteopontin). Similarly, 14 biomarkers associated with severity and mortality included pro-inflammatory cytokines and their receptors (sTNFRII, STNFRI, sIL2a, IL6, MIP1a), neutrophils (elevated WBC, Neutrophils, TIMP1) and tissue remodelling (SCGF, EG3A). Nine biomarkers common across severity and thrombosis were angiogenesis (VEGF, LYVE1, Follistatin), acute phase response (SAP, AGP) and clot formation (Fibrinogen and PAPs).

Conclusion(s): The biomarker profile associated with poorer outcomes indicates an inflammatory response, endothelial cell disruption, hypercoagulability and hypercatabolism. This study has identified several biomarkers that may be useful indicators of disease severity and progression. Further work is needed to determine how these may be used to direct clinical management.